Clinical Trial: Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07817680) titled 'Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia' on Aug. 25.

Brief Summary: Heparin-induced thrombocytopenia (HIT) is a rare but serious immune complication of heparin exposure that paradoxically increases the risk of thrombosis. In patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), heparin is essential to prevent circuit clotting, yet contraindicated in HIT. Available alternatives carry significant limitations. Cangrelor, an intravenous reversible P2Y12 inhibitor, has shown promise in case reports and small series in this context, but no multicenter study exists. CATC...